Earnings call transcript: TG Therapeutics Q1 2026 misses EPS, stock surges

TG Therapeutics reported Q1 2026 revenue of $194.8M and EPS of $0.12, missing consensus on both metrics, but U.S. BRIUMVI net product revenue of about $195M exceeded guidance and rose 63% year over year. Management raised full-year 2026 U.S. revenue guidance to $885M-$900M and total global revenue guidance to about $925M, while highlighting $34.8M operating income, $19.8M net income, and $573M in cash. The stock surged 19.18% pre-market to $43.025 despite the EPS miss, reflecting confidence in BRIUMVI momentum and the pipeline.

Analysis

The market is pricing TGTX less like a quarterly earnings name and more like a durable re-rating story: the core asset is now behaving like a cash-generative franchise, so the EPS miss is being ignored in favor of visibility into a multi-year compounding base. That matters because once a biotech shifts from launch narrative to recurring utilization, sell-side models tend to lag actual demand for several quarters, which can keep multiple expansion going even after the stock has already doubled or tripled.

The near-term setup is asymmetric but fragile. The stock is now trading as if execution risk has been de-risked, which leaves it vulnerable to any sign that patient starts normalize, persistence flattens, or the quarterly revenue cadence lumpy because of reimbursement/timing effects. In other words, the same operating leverage that drives upside also creates downside convexity if growth slows even modestly; a 5-10% revenue miss could translate into a much larger de-rating because expectations are now elevated and the equity sits near technical exhaustion.

The more important second-order effect is competitive: a successful simplification of dosing and any step toward self-administration would not just add incremental sales, it could force incumbents to defend both infusion and home-use channels simultaneously. That increases switching costs and commercial complexity for rivals, especially if physician adoption is being driven by patient-requested starts rather than pure rep wins. The sub-Q program is therefore the key optionality: it can either justify another leg higher if data are clean, or become a dead-money catalyst if it slips, because the base business is already priced for strength.

Contrarian view: the consensus is treating buybacks and management confidence as evidence that the stock is cheap, but at this stage repurchases may be more about signaling than deep value. The better read is that the equity is no longer under-owned for fundamental reasons; it is under-owned only if the market underestimates how quickly the franchise can cross from launch to category scale. That makes the next 1-2 catalysts more important than the reported quarter itself.

Key Decisions for Investors

• Stay long TGTX on pullbacks only; use a 2-4 week entry window after the pre-market gap to avoid chasing an overbought tape. Risk/reward is still favorable if the next data readouts confirm dose simplification or sub-Q progress, but upside is likely to come in bursts rather than straight-line continuation.
• Buy near-dated TGTX put spreads against the existing long if you are forced to own it into the catalyst stack. The setup is vulnerable to an air pocket if either upcoming data item disappoints or the market starts to doubt persistence, and implied downside can reprice faster than upside after a 19% gap.
• Pair trade: long TGTX / short a basket of mature anti-CD20 or MS incumbents over the next 1-3 months. The trade works if the market continues to reward product-cycle differentiation and patient-installed-base growth, while the short leg hedges sector beta and competitive read-throughs.
• If holding through the sub-Q readout, take partial profits into strength ahead of year-end data. The asymmetric part of the story is the optionality, but once the stock discounts a successful launch path, the multiple can compress if timing slips by even one quarter.
• For event-driven accounts, structure a call spread into the next catalyst rather than outright shares. The name has already re-rated sharply, so the cleaner expression is to cap premium outlay and target another 10-20% upside on positive data while limiting damage if the growth narrative becomes consensus.